Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 2:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 15,608 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Skin and Connective Tissue Disease Clear all
Completed Phase 1Phase 2 Interventional Results available

Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers

NCT00074308
View directory record Official record
Conditions
Recurrent Melanoma, Stage III Melanoma, Stage IV Melanoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
imatinib mesylate, bevacizumab, pharmacological study, laboratory biomarker analysis
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
21 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 20, 2018 · Synced Oct 31, 2026, 2:13 PM EDT
Completed Phase 4 Interventional Results available

Adapalene BPO Gel Pump, Moisturizer SPF 30 and Foam Wash in Patients With Mild to Moderate Acne Vulgaris

NCT01951417
View directory record Official record
Conditions
Acne
Interventions
Adapalene/BPO Gel, Moisturizer SPF 30, Foam Wash
Drug · Other
Lead sponsor
Galderma R&D
Industry
Eligibility
9 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
5
States / cities
Boynton Beach, Florida • Nashville, Tennessee • Carrollton, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2022 · Synced Oct 31, 2026, 2:13 PM EDT
Completed Phase 2 Interventional Results available

Study of Safety and Tolerability of CFZ533 in Patients With Sjögren's Syndrome

NCT04541589
View directory record Official record
Conditions
Sjogren's Syndrome
Interventions
Iscalimab, Placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
7
States / cities
Suwanee, Georgia • Baton Rouge, Louisiana • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Oct 31, 2026, 2:13 PM EDT
Completed Not applicable Interventional

Metformin and Rosiglitazone, Alone or in Combination, in HIV-Infected Patients With Insulin and Fat Abnormalities

NCT00015691
View directory record Official record
Conditions
HIV Infections, Lipodystrophy, Hyperinsulinemia
Interventions
Metformin hydrochloride, Rosiglitazone maleate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
34
States / cities
Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2013 · Synced Oct 31, 2026, 2:13 PM EDT
Recruiting Phase 3 Interventional

Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

NCT05549297
View directory record Official record
Conditions
Advanced Melanoma
Interventions
Tebentafusp, Tebentafusp with Pembrolizumab, Investigators Choice
Drug
Lead sponsor
Immunocore Ltd
Industry
Eligibility
18 Years and older
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
25
States / cities
Phoenix, Arizona • Jacksonville, Florida • Orlando, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 31, 2026, 2:13 PM EDT
Completed Not applicable Interventional

Intervention to Improve the Delivery of Follow-up Care for Low-Risk Breast Cancer

NCT05609435
View directory record Official record
Conditions
Breast Cancer
Interventions
REASSURE
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 95 Years · Female only
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 31, 2026, 2:13 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Duke Autoimmunity in Pregnancy Registry

NCT00513591
View directory record Official record
Conditions
Pregnancy, Systemic Lupus Erythematosus, Cutaneous Lupus, Rheumatoid Arthritis, Sjogren's Syndrome, Scleroderma
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
513 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 23, 2019 · Synced Oct 31, 2026, 2:13 PM EDT
Withdrawn Phase 1 Interventional

Safety and Efficacy of HMI-203 in ERT-Treated Adults With MPS II

NCT05238324
View directory record Official record
Conditions
Mucopolysaccharidosis II
Interventions
Genetic HMI-203
Biological
Lead sponsor
Homology Medicines, Inc
Industry
Eligibility
18 Years to 45 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
5
States / cities
Oakland, California • New Haven, Connecticut • Hackensack, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2023 · Synced Oct 31, 2026, 2:13 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Sleep Intervention to Improve Outcomes Among Women at High Risk of Breast Cancer

NCT02613923
View directory record Official record
Conditions
Breast Cancer, Sleep
Interventions
GO! To Sleep, Sleep information, Blood Draw, Pittsburgh Sleep Quality Index (PSQI), Insomnia Severity Index (ISI), SF-12 quality of life survey
Behavioral · Procedure · Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
21 Years and older · Female only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 9, 2019 · Synced Oct 31, 2026, 2:13 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Evaluation of Adherence to Topical Agents: Applying Communication Technology to Improve Sunscreen Use

NCT00535769
View directory record Official record
Conditions
Skin Cancer
Interventions
Electronic + no text message, Electronic monitor + text messages
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 20, 2012 · Synced Oct 31, 2026, 2:13 PM EDT
Completed Phase 2 Interventional Results available

Explorative Trial Evaluating the Efficacy and Tolerability of LEO43204 in Moderate to Severe Acne

NCT02575950
View directory record Official record
Conditions
Acne Vulgaris
Interventions
LEO43204, Placebo
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years to 35 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Lomita, California
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Oct 31, 2026, 2:13 PM EDT
Terminated Phase 2 Interventional Results available

A Phase 2, Muti-Center Study of Repeat Dosing of Squaric Acid Dibutyl Ester in Subjects With Herpes Labialis

NCT03521479
View directory record Official record
Conditions
Herpes Labialis, HSV
Interventions
Squaric Acid Dibutyl Ester
Drug
Lead sponsor
Squarex, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Doral, Florida • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 6, 2021 · Synced Oct 31, 2026, 2:13 PM EDT
Completed Phase 1 Interventional

Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer

NCT01624441
View directory record Official record
Conditions
Estrogen Receptor Negative, HER2/Neu Negative, Male Breast Carcinoma, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7, Triple-Negative Breast Carcinoma
Interventions
Dinaciclib, Epirubicin Hydrochloride, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 30, 2018 · Synced Oct 31, 2026, 2:13 PM EDT
Withdrawn No phase listed Observational

A Pilot Study to Explore the Role of Gut Flora in Psoriasis

NCT04099979
View directory record Official record
Conditions
Psoriasis, Psoriasis Vulgaris, Psoriasis Universalis, Psoriasis Face, Psoriasis Nail, Psoriatic Plaque, Psoriasis Diffusa, Psoriasis Punctata, Psoriasis Palmaris, Psoriasis Circinata, Psoriasis Annularis, Psoriasis Genital, Psoriasis of Scalp, Psoriasis Geographica
Interventions
No Intervention
Other
Lead sponsor
ProgenaBiome
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 31, 2026, 2:13 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Exergaming Intervention and Breast Cancer Biomarkers in Black Women

NCT02152462
View directory record Official record
Conditions
Breast Cancer, Obesity
Interventions
Exergaming
Other
Lead sponsor
Georgetown University
Other
Eligibility
40 Years to 59 Years · Female only
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2019
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 10, 2020 · Synced Oct 31, 2026, 2:13 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Topical Cantharidin for the Treatment of Molluscum Contagiosum, Phase 2

NCT03017846
View directory record Official record
Conditions
Molluscum Contagiosum
Interventions
Cantharidin
Drug
Lead sponsor
Steven R Cohen
Other
Eligibility
2 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jan 30, 2019 · Synced Oct 31, 2026, 2:13 PM EDT
Completed Not applicable Interventional

Helping Women Stay Up-To-Date With Cancer Screening By Using a Prevention Care Manager or Usual Care

NCT00477646
View directory record Official record
Conditions
Breast Cancer, Cervical Cancer, Colorectal Cancer
Interventions
Prevention Care Management
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
50 Years to 64 Years · Female only
Enrollment
2,241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 5, 2011 · Synced Oct 31, 2026, 2:13 PM EDT
Recruiting Not applicable Interventional

Lean Beef as Part of a Healthy Meal Plan in Adolescents With Polycystic Ovary Syndrome (PCOS)/Polyendocrine Metabolic Ovarian Syndrome (PMOS)

NCT07780188
View directory record Official record
Conditions
PCOS (Polycystic Ovary Syndrome), Obese Adolescents, Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities, Overweight Adolescents, Irregular Menstrual Cycle, Irregular Menstrual Cycles, Hirsutism, Hyperandrogenism
Interventions
Beef+
Other
Lead sponsor
Texas A&M University
Other
Eligibility
11 Years to 17 Years · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 31, 2026, 2:13 PM EDT
Completed Phase 2 Interventional Results available

Vinflunine Plus Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2neu) Over-Expressing Metastatic Breast Cancer

NCT00284180
View directory record Official record
Conditions
Breast Neoplasms, Breast Cancer
Interventions
Vinflunine, Trastuzumab
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
10
States / cities
Anniston, Alabama • Fort Myers, Florida • Jacksonville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2013 · Synced Oct 31, 2026, 2:13 PM EDT
Not listed Not applicable Interventional

VR for Surgical Prehabilitation and Rehabilitation

NCT06334380
View directory record Official record
Conditions
Breast Cancer, Frailty, Surgery
Interventions
Virtual Reality Modules Only, Virtual Reality Modules + Live Physical Therapist Support
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Oct 31, 2026, 2:13 PM EDT
Completed Phase 2 Interventional Results available

Testing Effectiveness of Losartan in Patients With EoE With or Without a CTD

NCT01808196
View directory record Official record
Conditions
Eosinophilic Esophagitis, Connective Tissue Disorders
Interventions
Losartan Potassium
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
5 Years to 21 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Mason, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 24, 2020 · Synced Oct 31, 2026, 2:13 PM EDT
Completed Phase 4 Interventional

Evaluation of the Clinical Effectiveness of a Collagen-ORC Antimicrobial Matrix in Full-Thickness, Neuropathic Diabetic Foot Ulcers

NCT00235196
View directory record Official record
Conditions
Foot Ulcer
Interventions
Collagen ORC Antimicrobial Matrix (CAM)
Device
Lead sponsor
Ethicon, Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Timeline
2004 – 2005
U.S. locations
3
States / cities
Fort Lauderdale, Florida • South Miami, Florida • Warren, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 13, 2006 · Synced Oct 31, 2026, 2:13 PM EDT
Recruiting Not applicable Interventional

Evaluation of the Efficacy of Hyalomatrix® in the Healing of Chronic Venous Leg Ulcers

NCT07335861
View directory record Official record
Conditions
Venous Leg Ulcer, Chronic Wounds
Interventions
Hyalomatrix, Standard of Care
Device · Other
Lead sponsor
NuScience Medical Biologics, LLC
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
4
States / cities
Alexandria, Louisiana • Pineville, Louisiana • Vidalia, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 31, 2026, 2:13 PM EDT
Completed Early Phase 1 Interventional

Vaccine Therapy in Treating Patients With Previously Treated Stage II or Stage III Breast Cancer

NCT00640861
View directory record Official record
Conditions
Breast Cancer
Interventions
CpG oligodeoxynucleotide, HER-2/neu peptide vaccine, MUC-1 peptide vaccine, incomplete Freund's adjuvant, sargramostim, immunoenzyme technique, immunologic technique
Biological · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 31, 2018 · Synced Oct 31, 2026, 2:13 PM EDT